SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Life Scienc - Quaterly Results

08 Feb 2022 Evaluate
The company's total revenue for the quarter ended December 2021 saw a slight change in the total revenue, having registered a total revenue of Rs. 5224.99 millions.A humble growth in net profit of 11.09% reported in the quarter ended December 2021 to Rs. 1037.13  millions from Rs. 933.61 millions.A decline of 1495.98 millions was observed in the OP in the quarter ended December 2021 from 1552.00 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202112 202012 % Var
Sales 5224.99 5002.29 4.45 5224.99 5002.29 4.45 5224.99 5002.29 4.45
Other Income 35.34 3.72 850.00 35.34 3.72 850.00 35.34 3.72 850.00
PBIDT 1495.98 1552.00 -3.61 1495.98 1552.00 -3.61 1495.98 1552.00 -3.61
Interest 0.61 216.50 -99.72 0.61 216.50 -99.72 0.61 216.50 -99.72
PBDT 1495.37 1335.50 11.97 1495.37 1335.50 11.97 1495.37 1335.50 11.97
Depreciation 97.39 83.60 16.50 97.39 83.60 16.50 97.39 83.60 16.50
PBT 1397.98 1251.90 11.67 1397.98 1251.90 11.67 1397.98 1251.90 11.67
TAX 360.85 318.29 13.37 360.85 318.29 13.37 360.85 318.29 13.37
Deferred Tax 41.49 20.78 99.66 41.49 20.78 99.66 41.49 20.78 99.66
PAT 1037.13 933.61 11.09 1037.13 933.61 11.09 1037.13 933.61 11.09
Equity 245.05 19.60 1150.26 245.05 19.60 1150.26 245.05 19.60 1150.26
PBIDTM(%) 28.63 31.03 -7.72 28.63 31.03 -7.72 28.63 31.03 -7.72

Alivus Life Sciences Share Price

1066.65 -6.50 (-0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×